Further case control studies, namely, cohorts of fenofibrate vs. placebo treated patients, are needed to test the hypothesis that fenofibrate restores the percentage of CCR2+ non-classical monocytes leading to improvement of ventricular function in patients with Chagas disease. This evidence concerns the gene CCR2 and Chagas disease.